Pralsetinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 277 publications

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 26, 2026

GDNF-RET signaling drives pulmonary neuroendocrine cell hyperplasia and allergic airway inflammation.

GDNF-RET signaling drives pulmonary neuroendocrine cell hyperplasia and allergic airway inflammation.

Journal: FEBS letters

Published: March 09, 2026

Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study.

Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study.

Journal: Tumori

Published: February 06, 2026

Unlocking catalytic capacity of (S)-selective ω-transaminases toward aryl methyl ketones via pocket engineering and droplet screening.

Unlocking catalytic capacity of (S)-selective ω-transaminases toward aryl methyl ketones via pocket engineering and droplet screening.

Journal: Bioresource technology

Published: February 02, 2026

Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma.

Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma.

Journal: Pathology, research and practice

Published: January 21, 2026

FGFR3-TACC3 fusion as a potential primary resistance mechanism to EGFR-TKI in lung adenocarcinoma harboring co-driven mutations: a case report.

FGFR3-TACC3 fusion as a potential primary resistance mechanism to EGFR-TKI in lung adenocarcinoma harboring co-driven mutations: a case report.

Journal: Frontiers in oncology

Published: January 16, 2026

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry.

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 23, 2025

Sequential targeted therapy in synchronous dual-primary lung adenocarcinomas with EGFR and RET alterations: a 5-year follow-up case report.

Sequential targeted therapy in synchronous dual-primary lung adenocarcinomas with EGFR and RET alterations: a 5-year follow-up case report.

Journal: Frontiers in oncology

Published: December 17, 2025

Brief Report: Intestinal Lymphangiectasia with Selpercatinib and Pralsetinib Treatment.

Brief Report: Intestinal Lymphangiectasia with Selpercatinib and Pralsetinib Treatment.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 10, 2025

RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.

RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 07, 2025

Design, synthesis, and activity evaluation of RET protein degradation based on PROTAC and HyTTD techniques.

Design, synthesis, and activity evaluation of RET protein degradation based on PROTAC and HyTTD techniques.

Journal: Bioorganic & medicinal chemistry letters

Published: November 26, 2025

RET Receptor Tyrosine Kinase Promotes Breast Cancer Metastasis to the Brain and RET Inhibitors Pralsetinib and Selpercatinib Suppress Breast Cancer Brain Metastases.

RET Receptor Tyrosine Kinase Promotes Breast Cancer Metastasis to the Brain and RET Inhibitors Pralsetinib and Selpercatinib Suppress Breast Cancer Brain Metastases.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Showing 1-12 of 277

Last Updated: 04/28/2026